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Abstract Permanent cardiac pacing in pediatric patients
presents challenges related to small patient size, complex
anatomy, electrophysiologic abnormalities, and limited
access to cardiac chambers. Epicardial pacing currently
remains the conventional technique for infants and patients
with complex congenital heart disease. Pacemaker lead
failure is the major source of failure for such epicardial
systems.Theauthorshypothesizedthataretrocostalsurgical
approachwouldreducetherateofleadfailureduetofracture
compared with the more traditional subrectus and subxi-
phoid approaches. To evaluate this hypothesis, a retrospec-
tive chart review analyzed patients with epicardial
pacemaker systems implanted or followed at Rady Chil-
dren’s Hospital San Diego between January 1980 and May
2007. The study cohort consisted of 219 patients and a total
of 620 leads with epicardial pacemakers. Among these
patients, 84% had structural congenital heart disease,
and 45% were younger than 3 years at time of the ﬁrst
implantation. The estimated lead survival was 93% at
2 years and 83% at 5 years. The majority of leads failed due
to pacing problems (54%), followed by lead fracture (31%)
and sensing problems (14%). When lead failure was adjus-
ted for length of follow-up period, no signiﬁcant differences
in the rates of failure by pocket location were found.
Keywords Congenital heart disease  Electrophysiology 
Epicardial  Pacemaker
Permanent cardiac pacing in pediatric patients presents
many challenges related to small patient size, complex
anatomy, electrophysiologic abnormalities, and limited
access to cardiac chambers [1, 7, 10]. Although many ado-
lescent patients are well served by transvenous pacemakers,
epicardial pacing currently remains the conventional tech-
nique for infants and those with complex congenital heart
disease [9, 10]. Epicardial pacemaker leads must be afﬁxed
to the outer surface of the heart by direct application in the
operating room. Because of the complex cardiac anatomy,
lack of pediatric-speciﬁc devices, and variable surgeon
training and experience, a range of surgical techniques have
evolved [14]. These techniques include different surgical
approaches (partial or full sternotomy, subxyphoid, thora-
cotomy), generator pocket location (retrocostal, subrectus,
subxyphoid), and various lead ﬁxation methods.
Findings have shown that epicardial lead placement is a
risk factor for lead failure compared with transvenously
placed leads [6, 11]. Historically, the pacemaker generator
pocket has been formed in the abdominal wall within the
rectus abdominus muscle sheath, typically at the level of
the umbilicus. At the institution where this study was
conducted, this approach is termed subrectus.
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DOI 10.1007/s00246-010-9754-1In 1999, surgeons at Rady Children’s Hospital, San
Diego, California began implanting generators closer to the
heart, using either a subxiphoid pocket location or posi-
tioning the generator pocket in an intrathoracic location,
which we term the retrocostal approach. With the retro-
costal approach, the generator and coils of redundant leads
are positioned posterior to the rectus muscle at a location
behind the lower margin of the rib cage.
The rationale for the retrocostal approach was to avoid
the exposed nature of the epicardial leads as they traverse
from the abdomen superiorly into the mediastinum and to
leave the leads and device in a ‘‘protected’’ pocket behind
the rib cage. We hypothesized that the retrocostal approach
would reduce the rate of lead failure due to fracture. This
study aimed to assess lead survival characteristics among
our epicardial pacemaker patients to determine whether the
retrocostal pocket location was associated with increased
lead survival compared with the subrectus and subxiphoid
pocket locations and to examine risk factors for epicardial
lead failure in this patient population.
Methods
Design and Subjects
We undertook a retrospective chart review of all patients
with epicardial pacemaker systems implanted or followed
at Rady Children’s Hospital–San Diego between January
1980 and May 2007. Institutional review board approval
was obtained before data collection. Patients were identi-
ﬁed by review of medical records and our surgical data-
base. Transvenous pacemaker systems and leads placed
prophylactically were excluded from the analysis. Patients
whose devices were implanted outside our institution were
included in the study when adequate follow-up evaluation,
pocket location, and variables of their implanted devices
were documented.
Data Collection
We reviewed all medical records in hard and soft copy
for the purposes of our study. These included electronic
databases, paper charts, and surgical and electrophysiolog-
ical records. The demographic and clinical variables col-
lected were date of birth, gender, height and weight at the
time of the implantation and the latest follow-up evaluation,
anatomic and electrophysiologic diagnosis, and number of
prior operations. When patient height or weight were not
available for a device implantation procedure, we used two
to three points on the patient’s plotted growth curve
(National Center for Health Statistics 2000, 3rd to 97th
percentile charts) and extrapolated the curve to determine
the patient’s approximate implant dimensions. The implan-
tation procedure-related variables collected were pocket
location (derived from the surgeon’s operative notes and
conﬁrmed using radiography and follow-up records when-
ever possible), the implantation date, and the implanting
surgeon.Thelead-speciﬁcvariablescollectedwerethemake
and model of the lead (and associated manufacturing details
such polarity, insulation material, steroid-eluting proper-
ties), lead tip location (epicardial or transmural-endocar-
dial), lead chamber (atria or ventricle), lead functional
characteristics (implant and latest follow-up capture
threshold, sensing, and impedance), lead failure (yes/no),
and lead failure type described in the following discussion.
Deﬁnitions
We deﬁned a lead’s lifetime from the implantation date to
the date of documented lead failure, removal, or latest fol-
low-up date within the study period. If the pocket location
was changed and an existing lead reused, the lead was
censored at the time of pocket relocation. When an appar-
ently normally functioning lead was removed or replaced
(elective replacement), the latest follow-up date was recor-
ded, and the lead was censored. Other outcomes recorded
included patient death, heart transplantation, abandonment
of pacing system, patient lost to follow-up evaluation, or
completionofthestudyperiod.Failuretypewasnotedforall
failed leads whenever possible and categorized as proven
lead fracture by direct inspection or radiograph, pacing
problems such as failure to capture or unacceptably high
capture threshold, clinically signiﬁcant sensingproblems,or
suspected lead fracture due to lead impedance or cause
otherwise not speciﬁed.
Surgical Technique
The standard techniques for creation of subrectus and sub-
xiphoid pacemaker pockets have been reviewed elsewhere
[8]. The retrocostal approach is performed as follows. An
entry into the left posterior rectus sheath is made near the
lower margin of the sternotomy incision, and a pocket is
developed within the rectus sheath. The upper margin of the
rectus sheath is delimited by its attachment to the subcostal
margin. This attachment is carefully dissected off the ribs to
permit extension of the pocket cephalad, beyond and pos-
terior to the subcostal margin. Care is taken to remain
extrapleural in the cephalad extension of the pocket.
The pacemaker generator is positioned within the pocket
so as to be almost entirely retrocostal. An anchoring suture
securesthegeneratortotheperiosteumoftheribstopreventit
from migrating outside the protection of the overlying rib.
Theheaderofthegenerator,withleadattachments,isentirely
posterior to the ribs, so the course of the leads never emerges
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123from the protection of the overlying rib cage. This method is
in contradistinction to the prior method of the rectus sheath
pocket, in which the leads pass over the abdominal wall to
course into the pericardial envelope (Fig. 1).
Statistical Analysis
For the primary outcome analysis, the patient cohort was
divided into three groups based on the pocket location used
(retrocostal, subxiphoid, or subrectus). Kruskal–Wallis
one-way analysis of variance by ranks was used for testing
equality of population medians among the three groups.
Lead survival as a function of pocket location was plotted
using Kaplan–Meier analysis. The resulting survival curves
were assessed for statistical difference using the log-rank
test. The chi-square test was used to test for an association
between lead failure type and pocket location.
For our secondary outcome analysis, we tested candidate
variables for correlation with lead failure in the entire
cohort. Both patient- and lead-speciﬁc variables were
examined. For other patient-speciﬁc variables, Cox pro-
portional hazard analysis was performed using the patient
as the unit of analysis and modeling on time to the ﬁrst lead
failure. Each patient was entered only once. For lead-spe-
ciﬁc variables, the lead was considered the primary unit of
analysis. A patient could have more than one lead failure.
Multivariate analyses were performed using Cox pro-
portional hazards, with an entry criteria of univariate
p value less than 2. Conﬁdence intervals (CI) at 95% are
presented for hazard ratios in Cox regression. The statis-
tical programming package of Stata/IC for Windows ver-
sion 10 (StataCorp, College Station, TX, USA) was used
for uni- and multivariate Cox proportional hazards analy-
sis. All other statistical analyses were performed using
SPSS, version 16 (SPSS Inc., Chicago, IL, USA).
A power analysis was conducted using Power and
Precision 3.0 (Biostat Inc, 2001, Englewood, NJ, USA).
For the described study design, sample size (number of
leads), attrition rate (0), alpha (p B 0.05) and tails (2), and
population effect size described earlier, the study had a
power of 83% to yield a statistically signiﬁcant result.
Results
Patient Characteristics
Our cohort consisted of 219 patients with a total of 620
leads that comprised the study sample. Of these patients,
107 were women, and 84% (183/219) had structural con-
genital heart disease. The majority of the patients were
young, with 45% younger than 3 years, and only 8% of the
patients 18 years or older at the time of the ﬁrst implan-
tation. The predominant indication for pacing was third-
degree heart block.
The cohort was divided into three groups by pocket
location. The majority of the patients had either a subrectus
or retrocostal pocket location. Demographic data for our
patient population were assessed for equivalence between
groups. Age, gender, weight, height, implant body surface
area, cardiac anatomy, pacemaker indication, and number
of prior surgeries were not signiﬁcantly different between
the three groups. The follow-up period was longer in the
subrectus pocket location group (Table 1).
Lead Characteristics
The median duration of lead follow-up assessment was
3.1 years (n = 620). The majority of leads were manufac-
tured by Medtronic (Minneapolis, MIN) (442/620, 71%),
Fig. 1 Chest radiographs demonstrating pocket locations. The typical
sites of epicardial pacemaker implantation are demonstrated from left
to right: retrocostal, subxiphoid, and subrectus. Notably, the
retrocostal location keeps all hardware within an intrathoracic
location, whereas the subrectus and subxiphoid pacemaker pockets
require that the pacemaker leads traverse the abdominal musculature
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123and 55% of the leads used were steroid eluting. Most of the
leads were silicone (77%), and slightly more than half of the
leads used a ‘‘screw-in’’ ﬁxation mechanism. As outlined in
Table 2, manufacturer, insulation material, steroid elution,
polarity, and ﬁxation methods differed between the groups
by pocket location (p = 0.01).
Procedural Characteristics
A total of 284 leads were placed in 99 patients using the
subrectus pocket location. The retrocostal approach was
used for 274 leads in 96 patients. For the remainder, a
subxiphoid pocket location was used (Tables 1, 2). The
Table 1 Patient demographics
Variable Subrectus Subxyphoid Retrocostal Total p Value
n 99 24 96 219 –
Demographic data (at ﬁrst implant)
a
Female (%) 49% 58% 46% 49% 0.541
Median age: years (range) 3.08 (0–30.04) 6.59 (0–37.84) 4.27 (0–39.51) 3.62 0.140
Median follow-up period: years (range) 5.32 (0.02–22.75) 3.53 (0.02–14.61) 2.77 (0.04–14.40) 3.69 \0.001
Median weight: kg (range) 11.9 (2.0–95.4) 18.1 (2.5–64.1) 15.9 (2.0–87.5) 14.0 0.168
Median height: cm (range) 86 (33–173) 104.5 (37–177) 99 (43–179) 96 0.188
Median body surface area: m
2 (range) 0.527 (0.15–2.03) 0.732 (0.17–1.75) 0.658 (0.15–1.98) 0.611 0.204
Median no. of prior surgeries: n (range) 2 (0–6) 1 (0–7) 2 (0–11) 2 0.114
Principal cardiac diagnosis: n (%) 0.397
Congenital structural heart disease 85 (85.9) 19 (79.2) 79 (82.3) 183 (83.6) –
Cardiomyopathy 3 (3.3) 0 (0) 3 (3.1) 6 (27.4) –
No structural heart disease 8 (8.1) 5 (20.8) 14 (17.7) 27 (12.3) –
Unknown 3 (3.3) 0 (0) 0 (0) 3 (1.6) –
Indication for device placement (n) 0.266
Arrhythmia, nonspeciﬁc (cardiac) 1012
Atrial ﬁbrillation 0011
Atrial ﬂutter 4149
Bradycardia (sinus) 3137
Functional disturbances after cardiac surgery 0011
Heart block 1 1012
Heart block 2 type 1 Wenckebach 0246
Heart block 2 type 2 Mobitz 4251 1
Heart block 3 (acquired) 38 10 25 73
Heart block 3 congenital 7 1 15 23
Junctional rhythm 0088
Junctional tachycardia 0011
Left bundle branch block 0011
Multifocal atrial tachycardia 0011
Sinus node dysfunction 38 7 24 69
Syncope 1001
Unknown 1012
Ventricular tachycardia 1 1
Total 99 24 96 219
Lead failure
b 62 (62) 7 (29) 26 (27) 95 (43) \0.001
Each patient is counted once in this analysis using ﬁrst implantation information. Patients may have had more than one lead and more than one
pocket location. The p values were derived from Kruskal–Wallis tests for demographic data. Categorical data for principal cardiac diagnosis and
indication for device placement were assessed with Pearson chi-square
a For continuous variables, median (range) is reported. For categorical variables the count (n) is listed as well as the percentage within that
pocket location subgroup (%)
b No. of patients who experienced one or more lead failures during the study period
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123implanting surgeon was recorded for 583 of 620 leads
(94%). A total of 11 surgeons implanted one or more of the
620 leads analyzed. Of these 11 surgeons, 3 accounted for
83% (518/620) of the procedures. Most of the retrocostal
implants (84%, 230/274) were performed by a single
surgeon.
Lead Failure
Overall, 43% (95/219) of the patients experienced one or
more lead failures during a median follow-up period of
3.7 years, and 28% (173/620) of the leads failed during a
mean follow-up period of 3.1 years. The estimated lead
survival was 93% at 2 years and 83% at 5 years. The
majority of the leads failed due to pacing problems (54%,
93/173) (e.g., high pacing thresholds), followed by lead
fracture (31%, 53/173) and sensing problems (14%,
24/173). When divided into groups by pocket location, the
majority of lead failures were seen in the subrectus group
(116/173). Overall, 40% of the leads using this pocket
location failed compared with 16% and 17% of the leads
placed in subxiphoid and retrocostal locations, respectively
(p = 0.001). However, when adjustment was made for
length of follow-up evaluation, the rates of failure by
implant location did not differ signiﬁcantly (Fig. 2,
Table 3). In general, chi-square analysis showed no sig-
niﬁcant differences of lead failure cause by implant site
(Fig. 3). There were no statistical differences between lead
failure rates and the implanting surgeon.
Risk Factors for Lead Failure
Consistent with the Kaplan–Meier analysis, a univariate
Cox proportional hazard analysis failed to show any
differences between implant location and risk of fail-
ure (Table 4). This variable was tested using both a
Table 2 Lead characteristics by pocket location
Variable Subrectus Subxyphoid Retrocostal Total p Value
n (%)
a n (%) n (%)
n 284 62 274 620 –
Manufacturer: n (%) \0.001
Medtronic 205 (72.2) 57 (91.9) 180 (65.7) 442 (71.3) –
Guidant (CPI) 15 (5.3) 1 (1.6) 86 (31.4) 102 (16.5) –
St. Jude Medical 0 (0) 0 (0) 0 (0) 0 (0) –
Intermedics 37 (13.0) 2 (3.2) 1 (0.4) 40 (6.5) –
Unknown 27 (9.5) 7 (11.3) 2 (0.7) 36 (5.8) –
Steroid-eluting: n (%) \0.001
Steroid-eluting 91(32.0) 47 (75.8) 206 (75.2) 344 (55.5) –
Non–steroid-eluting 166 (58.5) 13 (21.0) 61 (22.2) 240 (38.7) –
Unknown 27 (9.5) 2 (3.2) 7 (2.6) 36 (5.8) –
Polarity: n (%) \0.001
Bipolar 46 (16.2) 16 (25.8) 172 (62.8) 234 (37.7) –
Unipolar 211 (74.3) 44 (71.0) 95 (34.7) 350 (56.5) –
Unknown 27 (9.5) 2 (3.2) 7 (2.6) 36 (5.8) –
Insulation material: n (%) \0.001
Silicone 181 (63.7) 59 (95.2) 247 (90.1) 480 (77.4) –
Polyurethane 16 (5.6) 1 (1.6) 17 (6.2) 34 (5.5) –
Unknown 27 (9.5) 2 (3.2) 7 (2.6) 36 (5.8) –
Fixation mechanism: n (%) \0.001
Screw-in 132 (46.5) 11 (17.7) 206 (75.2) 349 (56.3) –
Sew-on 68 (23.9) 43 (69.4) 58 (21.2) 169 (27.3) –
Stab-in 57 (20.0) 6 (9.7) 3 (1.1) 66 (10.7) –
Unknown 27 (9.5) 2 (3.2) 7 (2.6) 36 (5.8) –
Each lead is used as the unit of analysis. Patients may have more than one lead. If the pocket location is changed and a functioning lead is left in
situ, the lead is censured at the time of pocket change. Due to the study’s constraints, with access limited to only our in-house medical records,
we were unable to obtain every variable for every lead in our study. Analyses were conducted with unknowns as missing values, which did not
change the p values in our chi-square tests. Categorical data for the variables were assessed with Pearson chi-square. Lead fracture grouping
includes proven lead fracture, suspected lead fracture, and lead impedance
a % indicates the percentage of leads within that implantation location subgroup
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123patient- and lead-speciﬁc analysis. Other candidate vari-
ables were tested, with none proving a signiﬁcant relation
to risk of failure. The patient-dependent variables included
number of prior surgeries, age at ﬁrst implantation, size,
and presence of congenital heart disease. The lead-speciﬁc
variables included brand, steroid elution, insulation mate-
rial, ﬁxation mechanism, and polarity.
Discussion
Previous studies have demonstrated an increased risk for
failure of epicardial leads versus transvenous pacing sys-
tems. However, epicardial lead systems remain the tech-
nique of choice for patients who are either too small or
possess contraindications to standard transvenous lead
placement.
This study, the largest epicardial lead survival study to
date, aimed to determine whether the risk of lead failure
could be modiﬁed by pocket location, speciﬁcally by
comparing lower rectus versus subxiphoid versus implan-
tation behind the lower costal margin (retrocostal). Despite
analysis of 620 leads in 219 patients over a median follow-
up period longer then 3 years, we were unable to show any
statistically signiﬁcant beneﬁt of one pocket location over
another. Secondary analysis of a number of both patient-
and lead-speciﬁc variables also failed to identify any
predictors of lead failure.
We were unable to demonstrate a statistically signiﬁcant
advantage of the retrocostal pocket location over other
pocket locations in terms of lead fracture prevention.
Qualitatively, however, the data (Fig. 3) suggest that lead
failure by this mechanism appears to be less frequent with
the retrocostal implantation technique. Although admittedly
Fig. 2 Kaplan–Meyer survival
curve for epicardial pacemaker
leads by pocket location.
Cumulative lead longevity,
deﬁned as freedom from lead
failure for any reason, does not
differ between retrocostal,
subrectus, and subxiphoid
pacemaker pocket locations
(p = 0.491, Mantel-Cox)
Table 3 Lead failure by pocket location
Variable Subrectus Subxyphoid Retrocostal Total p Value
n (%)
a n (%) n (%)
n 284 62 274 620 –
Lead failure 116 (40.8) 10 (16.1) 47 (17.2) 173 (27.9) 0.002
Cause of lead failure
a – – – – 0.194
Lead fracture 38 (32.8) 3 (30) 12 (25.5) 53 (30.6) –
Pacing problems (NOS) 62 (53.5) 7 (70) 24 (51.1) 93 (15.0) –
Sensing problems (NOS) 13 (11.2) 0 (0) 11 (23.4) 24 (13.9) –
Unknown 3 (2.6) 0 (0) 0 (0) 3 (1.7) –
No lead failure 168 (59.2) 52 (83.9) 227 (82.9) 447 (72.1) –
a The cause of lead failure is not shown to be statistically different when stratiﬁed by lead failure versus nonfailure (p = 0.194, Pearson chi-
square). See Fig. 3 for graphic representation
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123not rigorously supported by the data in this report, it is the
authors’ practice for patients with a retrocostal implant who
are not pacemaker dependent to liberate them from the
contact sports restrictions that typically accompany the
alternative implant locations.
The relative surgical risk of the various implantation
techniques was not addressed in this study. The experience
of the surgeon performing the majority of the retrocostal
implantations indicates that the various implant locations
are comparable in terms of associated risks. At the primary
study institution, all epicardial generator changes were
performed by cardiothoracic surgeons, although this is an
institutional bias and does not reﬂect the suitability of these
procedures for an appropriately trained electrophysiologist.
Similar to the subxiphoid pocket location, generator change
or removal of a device in the retrocostal position can be
performed by reopening the subxiphoid incision and dis-
secting through the largely avascular planes deﬁned by the
pseudointima surrounding the generator. This does not
require a sternotomy. Generator changes or removals,
unless performed in combination with larger cardiac pro-
cedures, typically do not require an inpatient hospital stay.
Among leads, there were signiﬁcant differences in
manufacturer, steroid elution, polarity, insulation material,
and ﬁxation method when compared by group. We spec-
ulate that the differences between groups result from their
date of implantation. Our subrectus implantations were the
earliest epicardial surgeries performed at our center,
whereas the retrocostal and subxiphoid implantations were
the most recent.
During the study period, pacemaker leads were engi-
neered with newer insulation materials, bipolarity, and
steroid elution in attempts to improve their longevity [3].
Yet with all this, we still were impressed with the consis-
tency in the rate of lead failure across groups regardless of
lead characteristic or pocket location.
Fig. 3 Bar graph showing the
cause of lead failure by pocket
location expressed as the
proportion of total lead failures.
When lead failure is stratiﬁed by
cause, groups do show statistical
differences based on their
epicardial pacemaker pocket
location (retrocostal vs
subrectus vs subxiphoid;
p = 0.194, Pearson chi-square)
Table 4 Risk factors for lead failure (univariate analysis)
Variable HR p Value Lower
CI
Upper
CI
Patient variables
a
Pocket location (retrocostal) 1.06 0.807 0.66 1.71
No. of prior surgeries[2 1.47 0.067 0.97 2.24
Age at ﬁrst implant\12 years 0.93 0.778 0.55 1.56
Congenital heart disease 1.67 0.146 0.84 3.32
Linear growth rate C15 cm/
year
0.82 0.391 0.52 1.29
Height at ﬁrst implant
B70 cm
1.41 0.146 0.89 2.25
Weight at ﬁrst implant B8 kg 1.31 0.256 0.82 2.07
Age at ﬁrst implant C18 years 1.03 0.944 0.45 2.39
Age at ﬁrst implant
12–18 years
1.20 0.533 0.68 2.13
Lead variables
b
Pocket location (retrocostal) 1.014 0.938 0.71 1.44
Lead manufacturer:
Medtronic
0.740 0.062 0.54 1.02
Steroid-eluting 0.833 0.307 0.59 1.18
Insulation material: silicone 1.02 0.908 0.73 1.41
Fixation mechanism: sew-on 1.02 0.889 0.69 1.51
Polarity: bipolar 0.870 0.498 0.58 1.31
HR hazard ratio, CI conﬁdence interval
a Each patient is counted once, modeled on time to ﬁrst lead failure.
Some patients experienced more than one lead failure
b Each lead is counted as a unique entity in this analysis
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123Previous lead survival studies have demonstrated
remarkable consistency in estimated lead survival despite a
broad period and range of techniques covered. For exam-
ple, Fortescue et al. [6] undertook a retrospective analysis
of all pediatric pacemaker placements between 1980 and
2002 at a single pediatric hospital. They identiﬁed 1,007
leads in 497 subjects, 523 of which were epicardial leads.
Consistent with the practices at other centers, epicardial
leads were more often used in younger children and those
with congenital heart disease. These two factors were
found in both single and multivariate analysis to be inde-
pendent correlates of reduced lead longevity. Similarly,
epicardial placement also was an independent correlate
with lead failure. As in our study, the steroid-eluting versus
noneluting leads showed no difference in lead longevity for
epicardial devices (Fig. 4). Although the 5-year survival
rate for their epicardial leads approached 85%, compared
with approximately 75% in our study, the median age at
implantation was 9 years compared with 3.62 years in our
study.
Smerup et al. [12] undertook a prospective study
attempting to quantify risk among 61 patients. Germane to
this discussion, they too found that the epicardial leads, low
age at implantation, and high risk-adjusted congenital heart
surgery (RACHS) score were signiﬁcant predictors for
early device mortality. Approximately 50% of all their
patients had their ﬁrst device 5 years after implantation.
Cohen et al. [2] provides another comparison for our
study. Between 1983 and 2000, these authors had 123
patients with 207 epicardial leads. The median age at
implantation was 4.1 years, and 84% of the patients had
underlying structural congenital heart disease. The 5-year
lead survival rate among this population was 74%. Similar
failure rates were seen in Epstein et al. [5], with 33
epicardial patients and a 60% lead survival at 6 years;
Dodge-Khatami et al. [4], with 41 children and an 86%
lead survival at 5 years; and Thomson et al. [13], with 326
patients and a lead survival of 50% to 76% at 5 years.
Study Limitations
Because our study was retrospective, our analysis was
limited in scope. We were not able to control for surgeon
technique or device preference. Similarly, due to the
technological evolution of pacemakers and leads, lead
characteristics signiﬁcantly differed by implant location.
For example, the subrectus group included more non–
steroid-eluting leads than the subxiphoid or retrocostal
group. Nevertheless, we were surprised to see that not only
was the null hypothesis not disproven, but our risk model
also was statistically not signiﬁcant. It would appear that
our pediatric epicardial pacemaker population, with its low
median age, preponderance of congenital structural heart
disease, and multiple surgeries, does not accommodate
itself to an internal risk model because the vast majority of
patients already possess the known risk factors for early
lead failure.
Conclusions
Based on the outcomes of this study and a review of the
current literature, we conclude that the retrocostal approach
is neither superior nor inferior to the subrectus or subxi-
phoid approach in terms of lead longevity and freedom
Fig. 4 Kaplan–Meyer survival
curve for epicardial pacemaker
leads by (non)steroid elution.
For all leads for all pacemaker
pocket locations, comparison of
steroid-eluting leads with non–
steroid-eluting leads shows no
signiﬁcant difference in lead
longevity (p = 0.244, Mantel-
Cox)
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123from failure. Identifying modiﬁable risk factors that may
have an impact on epicardial lead survival remains
challenging.
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